Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 52, Issue 7, 2007, Pages 639-644

  Isikoglu, Mete ^a   Ozgur, Kemal ^b   Oehninger, Sergio ^b  

^a Antalya IVF   (Turkey)

^b NONE

Author keywords

Gonadotropin releasing hormone; Gonadotropin releasing hormone agonist; Intracytoplasmic sperm injections; Luteal phase; Ovarian stimulation

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE;

ARTICLE; BIRTH RATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; NIDATION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; EMBRYO IMPLANTATION; EMBRYO TRANSFER; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; LUTEAL PHASE; LUTEINIZING HORMONE; MALE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 34547096003     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Smitz J, Ron ELR, Tarlatzis BC: The use of gonadotropin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: Experience from three centers. Hum Reprod (suppl 1) 1992;7:49-66
2. Daya S: Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev [serial online] 2000;2:CD001299
3. Fujii S, Sato S, Fukui A, et al: Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod 2001;16:1671-1675
4. Valbunea D, Pellicer A, Guanes PP, et al: Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in vitro fertilization. Hum Reprod 1997;12:2118-2122
5. Raga F, Casan E, Ruiz A, et al: Gonadotrophin-releasing hormone agonist administered throughout the luteal phase and early pregnancy increases the fecundity in IVF-embryo transfer patients (abstr). Proc 14th annual meeting of European Society of Human Reproduction and Embryology, Gothenburg. Hum Reprod 1998;13:0-184
6. Weissman A, Shoham Z: Favourable pregnancy outcome after administration of a long-acting gonadotrophin-releasing hormone agonist in the mid-luteal phase. Hum Reprod 1993;8:496-497
7. Balasch J, Martinez F, Jove I, et al: Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in vitro fertilization patients. Hum Reprod 1993;8:1148-1151
8. Cahill DJ, Fountain SA, Fox R, et al: Outcome of inadvertent administration of gonadotrophin-releasing hormone agonist (buserelin) in early pregnancy. Hum Reprod 1994;7:1243-1246
9. Elefant E, Biour B, Blumberg-Tick J, et al: Administration of a gonadotropin-releasing hormone agonist during pregnancy: Follow-up of 28 pregnancies exposed to triptoreline. Fertil Steril 1995;63:1111-1113
10. Smitz J, Camus M, Devroey P, et al: The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 1991;6:290-293
11. Chang M-Y, Chiang C-H, Hsieh T-T, et al: Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998;69:505-510
12. Narayanan M, Murthy PS, Munaf SA, et al: Antiovarian antibodies and their effect on the outcome of assisted reproduction. J Assist Reprod Genet 1995;12:599-605
13. Tesarik J, Sousa M: Key elements of a highly efficient intracytoplasmic sperm injection technique: Ca2+ fluxes and oocyte cytoplasmic dislocation. Fertil Steril 1995;64:770-776
14. Balaban B, Urman B, Isiklar A, et al: The effect of pronuclear morphology on embryo quality parameters and blastocyst transfer outcome. Hum Reprod 2001;16:2357-2361
15. Meldrum DR, Wisot A, Hamilton F, et al: Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 1989;51:455-459
16. Toner JP, Brzyski RG, Oehninger S, et al: Combined impact of the number of pre-ovulatory oocytes and cryopreservation on IVF outcome. Hum Reprod 1991;6:284-289
17. Oehninger S, Toner JP, Veeck LL, et al: Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with or without a gonadotropin-releasing hormone agonist. Fertil Steril 1992;57:620-625
18. Brzyski RG, Muasher SJ, Droesch K, et al: Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. Fertil Steril 1988;50:917-921
19. Muasher SJ: Use of gonadotrophin-releasing hormone agonists in controlled ovarian hyperstimulation for in vitro fertilization. Clin Ther (suppl) 1992;14:74-86
20. Scott RT, Navot D: Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61:880-885
21. Pantos K, Meimeth-Daimanaki T, Vaxevanoglou T, et al: Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program Fertil Steril 1994;61:709-713
22. Faber BM, Mayer J, Cox B, et al: Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril 1998;69:826-830
23. Fujii S, Sagara M, Kudo H, et al: A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1997;67:1166-1168
24. Cramer DW, Powers DR, Oskowitz SP, et al: Gonadotropin releasing hormone agonist use in assisted reproduction cycles: The influence of long and short regimens on pregnancy rates. Fertil Steril 1999;72:83-89
25. Tasdemir M, Tasdemir I, Kodama H, et al: Is long protocol gonadotrophin releasing hormone agonist administration superior to short protocol in ovarian stimulation for in vitro fertilization? Int J Fertil Menopausal Stud 1995;40:25-28
26. Oppenheimer D, Bikkai H, Crowley W: Effects of chorionic GnRH analogue administration on gonadotrophin and alpha subunit secretion in post-menopausal women. Clin Endocrinol 1992;36:559-564
27. Smitz J, Erard P, Camus M, et al: Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992;7:1225-1229
28. Sungurtekin U, Jansen RPS: Profound luteinizing hormone suppression after stopping the gonadotrophin releasing hormone-agonist leuprolide acetate. Fertil Steril 1995;3:663-665
29. Chegini N, Ma C, Tang XM, et al: Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 2002;8:1071-1078
30. Wiznitzer A, Marbach M, Hazum E, et al: Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 1988;152:1326-1331
31. Srkalovic G, Wittliff JL, Schally AV: Detection and partial characterization of receptor for [Dtrip6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990;50:1841-1846
32. Chegini N, Rong H, Dou Q, et al: Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 1996;81:3215-3221
33. Pahwa GS, Kullander S, Vollmer G, et al: Specific low affinity binding sites for gonadotropin releasing hormone in human endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1991;41:135-142
34. Tesarik J, Hazout A, Mendoza C: Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004;19: 1176-1180
35. Tesarik J, Hazout A, Mendoza C: Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online [serial online] 2003